Bevacizumab-induced bowel perforation

Journal of the American Osteopathic Association

Volumn 111, Issue 7, 2011, Pages 437-441

  Sliesoraitis, Sarunas ^a   Tawfik, Bernard ^a  

^a WAKE FOREST UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; MONOCLONAL ANTIBODY;

CHEMICALLY INDUCED DISORDER; FEMALE; HUMAN; INCIDENCE; INTESTINE PERFORATION; MALE; NEOPLASM; PATHOLOGY; PROGNOSIS; REVIEW; RISK ASSESSMENT; SURVIVAL RATE;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; FEMALE; HUMANS; INCIDENCE; INTESTINAL PERFORATION; MALE; NEOPLASMS; PROGNOSIS; RISK ASSESSMENT; SURVIVAL RATE;

EID: 79960947508     PISSN: 00986151     EISSN: 19451997     Source Type: Journal    
DOI: None     Document Type: Review

References (29)

1. Zureikat AH, Mc-Kee MD. Targeted therapy for solid tumors: current status. Surg Oncol Clin N Am. 2008;17(2):279-301, 7-8.
2. Avastin [package insert]. South San Francisco, CA: Genentech, Inc; 2011. www.gene.com/gene/products/information/pdf/avastin-prescribing.pdf.
3. Richardson DL, Backes FJ, Hurt J, et al. Which factors predict bowel complications in patients with recurrent epithelial ovarian cancer being treated with bevacizumab? Gynecol Oncol. 2010;118(1);47-51.
4. Badgwell B, Feig BW, Ross MI, Mansfield PF, Wen S, Chang GJ. Pneu-moperitoneum in the cancer patient. Ann Surg Oncol. 2007;14(11):3141-3147.
5. Choi YI, Lee SH, Ahn BK, et al. Intestinal perforation in colorectal cancers treated with bevacizumab (Avastin). Cancer Res Treat. 2008;40(1):33-35.
6. Han ES, Monk BJ. What is the risk of bowel perforation associated with beva-cizumab therapy in ovarian cancer? Gynecol Oncol. 2007;105(1):3-6.
7. Roodhart JM, Langenberg MH, Witteveen E, Voest EE. The molecular basis of class side effects due to treatment with inhibitors of the VEGF/VEGFR pathway. Curr Clin Pharmacol. 2008;3(2):132-143.
8. Chéreau E, Stefanescu D, Selle F, Rouzier R, Daraï E. Spontaneous recto-vaginal fistula during bevacizumab therapy for ovarian cancer: a case report. Am J Obstet Gynecol. 2009;200(1):e15-e16.
9. Kamba T, Tam BYY, Hashizume H, et al. VEGF-dependent plasticity of fen-estrated capillaries in the normal adult microvasculature. Am J Physiol Heart Circ Physiol. 2006;290:H560-76.
10. Heinzerling JH, Huerta S. Bowel perforation from bevacizumab for the treatment of metastatic colon cancer: incidence, etiology, and management. Curr Surg. 2006;63(5):334-337.
11. Collins D, Ridgway PF, Winter DC, et al. Gastrointestinal perforation in metastatic carcinoma: a complication of bevacizumab therapy [published online ahead of print April 15, 2008]. Eur J Surg Oncol 2009;35(4):444-446.
12. Badgwell BD, Camp ER, Feig B, et al. Management of bevacizumab-asso-ciated bowel perforation: a case series and review of the literature. Ann Oncol. 2008;19(3):577-582.
13. Traina TA, Rugo HS, Dickler M. Bevacizumab for advanced breast cancer. Hematol Oncol Clin North Am. 2007;21(2):303-319.
14. McKoy JM, Patel J, Courtney DM et al. Bevacizumab-associated divertic-ulitis. Community Oncol. 2008;5(1):31-32.
15. Tol J, Cats A, Mol L, et al. Gastrointestinal ulceration as a possible side effect of bevacizumab which may herald perforation. Invest New Drugs. 2008;26 (4):393-397.
16. Hurwitz H, Saini S. Bevacizumab in the treatment of metastatic colorectal cancer: safety profile and management of adverse events. Semin Oncol. 2006;33(5 suppl 10):S26-S34.
17. Simpkins F, Belinson JL, Rose PG. Avoiding bevacizumab gastrointestinal toxicity for recurrent ovarian cancer by careful patient screening. Gynecol Oncol. 2007;107(1):118-123.
18. Kaye SB. Bevacizumab for the treatment of epithelial ovarian cancer: will this be its final hour? J Clin Oncol. 2007;25(33):5150-5152.
19. Lordick F, Geinitz H, Theisen J, Sendler A, Sarbia M. Increased risk of ischemic bowel complications during treatment with bevacizumab after pelvic irradiation: report of three cases. Int J Radiat Oncol Biol Phys. 2006;64(5): 1295-1298.
20. Kindler HL, Friberg G, Singh DA, et al. Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol. 2005;23(31):8033-8040.
21. Clinical study report: bevacizumab-Genentech, Inc. Genentech, Inc Web site. http://clinicalstudyresults.gene.com/avf2949g.pdf. Accessed July 5, 2011.
22. Gray J, Murren J, Sharma A, et al. Perforated viscus in a patient with non-small cell lung cancer receiving bevacizumab. J Thorac Oncol. 2007;2(6):571-573.
23. Wolf I, Urban D, Pfeffer R, et al. High incidence of fistula formation during bevacizumab treatment in rectal cancer patients. Acta Oncol. 2007;46(4):550-553.
24. Saif MW, Mehra R. Incidence and management of bevacizumab-related toxicities in colorectal cancer. Expert Opin Drug Saf. 2006;5(4):553-566.
25. Asmis TR, Chung KY, Teitcher JB, et al. Pneumatosis intestinalis: a variant of bevacizumab related perforation possibly associated with chemotherapy related GI toxicity. Invest New Drugs. 2008;26(1):95-96.
26. August DA, Serrano D, Poplin E. "Spontaneous," delayed colon and rectal anastomotic complications associated with bevacizumab therapy. J Surg Oncol. 2008;97(2):180-185.
27. Gordon MS, Cunningham D. Managing patients treated with beva-cizumab combination therapy. Oncology. 2005;69(suppl 3):25-33.
28. Micha JP, Goldstein BH, Rettenmaier MA, et al. A phase II study of outpatient first-line paclitaxel, carboplatin, and bevacizumab for advanced-stage epithelial ovarian, peritoneal, and fallopian tube cancer. Int J Gynecol Cancer. 2007;17(4):771-776.
29. Carboplatin and paclitaxel with or without bevacizumab in treating patients with stage III or stage IV ovarian epithelial, primary peritoneal cancer, or fallopian tube cancer. US National Institutes of Health Web site. http://clin-icaltrials.gov/ct/show/NCT00262847. Accessed July 5, 2011.